SUPPLY ISSUE Fluoxetine Hydrochloride Capsules
In June 2019, Mylan was awarded the tender for fluoxetine hydrochloride (Fluox) cap 20 mg, which was to begin 1 November 2019. There has since been a delay and Fluox has been unable to enter the market. Fluoxetine-Arrow is still listed on the Pharmaceutical Schedule and Teva has ordered in additional stock to help bridge the gap until Mylan is able to enter the market.
In order to ensure there is continued access to the product, PHARMAC will be removing stat dispensing for the capsule presentation from 11 November 2019 until further notice. There will be no change to the dispensing for the fluoxetine hydrochloride tab dispersible presentation.
The following Pharmacodes will be affected by the removal of stat dispensing:
Fluoxetine- Arrow Cap 20 mg 90 Pharmacode 2450860 Schedule price $1.99
Fluox Cap 20 mg 84 20 mg 84 Pharmacode 2353121 Schedule price $2.91
ProPharma / PWR have again been proactive and have set in place an allocation of 3 per customer per week.
We accept one size does not fit all, but in these instances where very little if any notice is provided we need to act on what stock remains available in the supply chain.
If you feel this unduly impacts on what your pharmacy requires or needs then you MUST discuss this with your Branch Manager or Key Account Manager.
Our Customer Services Team DO NOT have the authority to change allocation levels.
Together we can make this a seamless and painless transition.
We thank you in anticipation of your ongoing support.